CN1985978A - Compound preparation for reducing fat deposit in liver and alleviating fatty degeneration of liver cell - Google Patents
Compound preparation for reducing fat deposit in liver and alleviating fatty degeneration of liver cell Download PDFInfo
- Publication number
- CN1985978A CN1985978A CN 200610119578 CN200610119578A CN1985978A CN 1985978 A CN1985978 A CN 1985978A CN 200610119578 CN200610119578 CN 200610119578 CN 200610119578 A CN200610119578 A CN 200610119578A CN 1985978 A CN1985978 A CN 1985978A
- Authority
- CN
- China
- Prior art keywords
- liver
- rhizoma
- fat
- compound preparation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to health food technology, and is especially a kind of health care Chinese medicine preparation prepared with ginseng, red sage, haw, oriental water plantain, curcuma and other materials. Animal experiments show that the Chinese medicine preparation can reduce the body weight and liver weight of fatty liver rat effectively, reduce the fat deposit in liver of model rat and reduce fatty pathological change of liver cell, and no obvious inhibition on the liver function of fatty liver rat, no allergic reaction and other untoward reaction. The health care Chinese medicine preparation may be used in health food and preventing medicine for slimming and preventing and treating fatty liver.
Description
Technical field
The invention belongs to the health care of food field, be specifically related to a kind of contain medicine and food raw materials can blood fat reducing, protect the liver, slimming compound preparation.
Background technology
Along with improving constantly of living standard, people are more and more high to the nutrition health requirement of diet, when material life is abundant gradually, begin to pay close attention to the scientific and reasonable of diet, health should nutritiously be arranged again, otherwise, excess intake higher fatty acid, high-protein food causes very easily in the blood of human body that index such as blood fat raises, and causeing fat very, the person can cause some metabolic diseases, as coronary heart disease, fatty liver, diseases such as liver cirrhosis and diabetes have directly influenced modern's quality of life.Simultaneously,, the requirement of quality of life is also being improved constantly along with the requirement of people to quality of life, as keeping the beauty of outward appearance, relevant both at home and abroad lose weight and the medicine and the health product of blood fat reducing come out one after another.So effective, few side effects, but and the medicine of the reducing weight and blood fat that protects the liver of cheap and good-quality fat reducing and health food even cosmetics all become the focus that people pay close attention to.
Chinese herbal medicine clinically gropes and puts into practice to confirm that Chinese herb astragalus, Radix Salviae Miltiorrhizae, LUMBRICUS, Rhizoma Curcumae Longae, Fructus Crataegi, Rhizoma Chuanxiong, the Radix Rehmanniae, Fructus Toosendan, Poria, Hirudo, Semen Coicis, Radix Bupleuri, Semen Cassiae etc. are commonly used for the function of activating qi and collateral, blood activating and fat reducing, nourishing YIN to lower pathogenic fire through secular.And described medical material all belongs to the medicinal and edible Chinese medicine of national regulation.Motherland's traditional medicine, especially Chinese herbal medicine in blood fat reducing, aspect such as protect the liver, lose weight has special advantages and potentiality, and is little etc. as the performance of comprehensive each drug effect and toxic and side effects, caused the pay attention to day by day of relevant researcher both at home and abroad.
Summary of the invention
But the purpose of this invention is to provide the compound preparation that a kind of fat reducing protects the liver.Preparation of the present invention can reduce fat content, the liver protecting, helps simultaneously to lose weight, and nonhazardous helps to improve people's the health level and the beauty of outward appearance.
The present invention gropes to develop and has fat reducing, protects the liver and slimming compound Chinese medicinal preparation in the long-term practice of clinical treatment fatty liver.It is that effective ingredient and pharmaceutical carrier are made that compound preparation of the present invention adopts crude drug Radix Ginseng, Radix Salviae Miltiorrhizae, Fructus Crataegi, Rhizoma Alismatis, Rhizoma Curcumae Longae and Semen Cassiae, described effective ingredient is made up of following raw materials by weight percent medicine component: in per 100 gram finished products, Radix Ginseng 10-15%, Radix Salviae Miltiorrhizae 10-15%, Fructus Crataegi 15-25%, Rhizoma Alismatis 10-15%, Semen Cassiae 15-20%, Rhizoma Wenyujin Concisum 10-15%.
(in per 100 gram finished products) preferred weight percent of preparation of the present invention is Radix Ginseng 15%, Radix Salviae Miltiorrhizae 10%, Fructus Crataegi 25%, Rhizoma Alismatis 15%, Semen Cassiae 20%, Rhizoma Wenyujin Concisum 15%.
Preparation of the present invention wherein Radix Ginseng is an Araliaceae, and sweet, the little hardship of its nature and flavor has strongly invigorating primordial QI, invigorating the spleen to benefit the lung, promoting the production of body fluid to quench thirst, the effects such as increasing intelligence of calming the nerves; The Radix Salviae Miltiorrhizae Main Ingredients and Appearance can be divided into fat-soluble composition and water-soluble components, research has proved that the salvia-soluble composition has the very strong hemorheology that improves, and antiplatelet adheres to, assembles and discharges blood viscosity lowering, accelerate red cell velocity, increase erythrocyte membrane fluidity, microcirculation improvement, coronary artery dilator also has the effect of anti-hepatitis and early stage liver cirrhosis, its antioxidation also clearly, so can anti-cardiac-cerebral ischemia, blood lipid regulation has the saying of " Radix Salviae Miltiorrhizae merit with four things " simply; Fructus Crataegi has the effect of disappear trifoliate orange scale removal, blood circulation promoting and blood stasis dispelling; The Rhizoma Alismatis nature and flavor are sweet, and are cold, return kidney, urinary bladder channel, function diuresis, clearing away damp-heat; Rhizoma Curcumae Longae has the removing blood stasis circulation of qi promoting, eliminating blood stasis and inducing menstruation, wind dispelling pain relieving, the effect of stomach-invigorating and gall bladder-invigorating; Semen Cassiae sweet in the mouth, hardship, salty, cold nature is returned liver, kidney, large intestine channel, in recent years, studies confirm that, and it can not only item, the effect of blood lipid regulation, blood pressure lowering in addition.
The above-mentioned raw materials medicine all belongs to the Chinese medicine of the medicine-food two-purpose of national regulation.
Compound preparation of the present invention prepares by following method:
Get Rhizoma Alismatis and Rhizoma Curcumae Longae and in apparatus,Soxhlet's, extract earlier volatile oil, medicinal residues and all the other crude drug added 10 times of amounts of water for the first time with frying in shallow oil after extraction finished, and decocted 2h, incline and medical filtration, medicinal residues add 8 times of amounts of water again, decoct 1h, and inclining medical filtration, merge 2 times fried liquid, concentrate the volatile oil that the back adds Rhizoma Alismatis and Rhizoma Curcumae Longae, mixing, the adjustment drug level is 0.835g/ml.It is heavy that preparation of the present invention can be carried wine through water, makes extractum.
Compound preparation of the present invention is through zoopery, and the result proves that the body weight regulating liver-QI that can effectively alleviate the fatty liver rat weighs, obviously reduces rat model intrahepatic fat deposition, alleviates the pathological change of hepatic cell fattydegeneration, is suitable for the health care prevention of simple fatty liver.
Description of drawings
Fig. 1 respectively organizes hepatic tissue HE dyeing, * 200.
Fig. 2 respectively organizes the hepatocellular degeneration integration relatively.
Fig. 3 respectively organizes the dyeing of hepatic tissue oil red, * 100.
Fig. 4 respectively organizes hepatocyte oil red dyeing fat to drip integration relatively.
Fig. 5 respectively organizes hepatocyte oil red dyeing fat to drip the area quantitative analysis relatively,
Wherein: compare * P＜0.01 with model group.
The specific embodiment
1, laboratory animal: SPF level male Wistar rat is provided by Shanghai Univ. of Traditional Chinese Medicine's Experimental Animal Center, about body weight 140g, and totally 41.Ad lib is fed.
2, feedstuff: high lipid food is made up of normal diet, 2% cholesterol, 10% Adeps Sus domestica.
3, medicine and reagent:
1) preparation of the present invention contains Radix Ginseng 15%, Radix Salviae Miltiorrhizae 10%, Fructus Crataegi 25%, Rhizoma Alismatis 15%, Semen Cassiae 20%, Rhizoma Wenyujin Concisum 15% in per 100 gram finished products, and it is heavy to carry wine through water as stated above, makes extractum.
2) cholesterol is available from Guangzhou Mantidis Fine Chemical Works.Adeps Sus domestica refines voluntarily.Each biochemical measurement test kit all builds up bio-engineering research institute available from Nanjing.
4, experimental technique
Experiment grouping: adopt lottery rat to be divided into 10 of normal group at random, 16 of model group, 15 of treatment groups.
Modelling: normal rats is fed normal diet, and model group, treatment group are fed high fat diet respectively.Treatment group simultaneously gavages Chinese medicine preparation 2ml/100g every day, and normal group and model group then give normal saline 2ml/100g every day.Continuous 8 weeks.
Collection of specimens: behind the last administration 24h, weigh earlier, inject % pentobarbital anesthesia again, venous blood samples is won liver and spleen and is weighed.After observing cardinal principle liver outward appearance, leave and take liver and do 10% formaldehyde fixed and the freezing embedding of OCT.
Main observation and detection index: light microscopy checking: get liver organization, 10% formaldehyde fixed 24h, the routine paraffin wax embedded section, HE dyeing, frozen section is cooked oil red dyeing, does hepatopathy observation of science respectively.Biochemical detection: detect serum glutamic pyruvic transminase (ALT), glutamic oxaloacetic transaminase, GOT (AST), total bilirubin (TBiL), alkali phosphatase (ALP), glutamyl transpeptidase (GGT) etc.; Detect hepatic tissue triglyceride (TG) content.
Statistical procedures: measuring parameter adopts mean ± standard deviation to represent, does variance analysis and Q check with SPSS12.0 statistics software.Count parameter is with X
2Check, the sxemiquantitative count parameter is checked with the Riddit method.
5, experimental result:
Overview: normal group and model group rat body weight obviously increase, but treatment group body weight obviously alleviates than last 2 groups of rats, and significant difference (P＜0.01) is arranged.The liver weight of model group rat obviously increases, and treatment group liver recondition is to normal level.The heavy there was no significant difference of the spleen of 3 groups of rats.
Table 1 is the heavy and spleen anharmonic ratio of group rat body weight liver than (MEAN ± SD)).
Table 2 is respectively to organize liver tissues of rats HE dyeing hepatocellular degeneration size scale.
Table 3 is respectively to organize liver tissues of rats oil red dyeing fat to drip the sxemiquantitative size scale.
Table 4 is respectively to organize liver tissues of rats oil red dyeing fat titration size scale.
Table 5 is respectively to organize the quantitative analysis of liver tissues of rats oil red dyeing area.
Table 1.
| Group (n) | Body weight (g) | Liver heavy (g) | Spleen heavy (g) |
| Normal group (10) model group (16) treatment group (15) | 327±14 324±20 282±11*** | 11.26±0.76 12.30±1.17# 11.01±0.71*** | 0.76±0.12 0.79±0.10 0.73±0.12 |
Annotate: # compares P＜0.05 with normal group, * * * compares P＜0.01 with model group
The liver gross examination of skeletal muscle: the normal rats liver is no abnormal, and model group rat liver volume increases, and color is pale yellow, the quality deliquescing, and the peplos anxiety, the edge circle is blunt, and tangent plane is greasy.Treatment group liver volume is little, buff, and quality is medium, and the edge is blunt slightly, and tangent plane is greasy slightly.
Liver om observation: HE dyeing sees that the normal rats hepatic cords arranges normally, and the hepatocyte form is normal, nuclear circle, big, placed in the middle, and no fat drips and accumulates in the endochylema, the interior NIP cellular infiltration of lobule.The disorder of model group rat leaflet structure, hepatocellular degeneration is with the most obvious around the central vein, cell volume increases, have a large amount of fat to drip cavity in the endochylema, nuclear occupies the limit, does not see hepatic fibrosis, though treatment group rat degeneration hepatocyte is counted sxemiquantitative and reduces (see figure 1) than model group, statistical result shows difference not remarkable (seeing Table 2), but as calculate 1 fen statistics with each plus sige, between then organizing the significant difference (see figure 2) is arranged.Observation hepatic tissue fat drips through oil red dyeing treatment group fat and obviously lacks (see figure 3) than model group under the mirror, but its fat drips the distribution semi-quantitative analysis not to be demonstrated than model group significant difference (seeing Table 3) is arranged, and calculate 1 fen statistics with each plus sige, then between the group significant difference (see figure 4) is arranged also; Mirror is observed down hepatic tissue oil red its fat that dyes and is dripped distribution area and handle through image analysis system, and every slice, thin piece is got 3 visual field statistical analysiss, and significant difference (see Table 5, Fig. 5) is arranged between group.The analysis of hepatocyte fat set shows that the degeneration of model group rat hepatocytes is dripped based on bulla fat, and the degeneration of treatment group rat hepatocytes is then dripped based on vesicle fat, has significant significant difference (seeing Table 4).
Table 2.
| Group | n | The degeneration hepatocyte | |||
| - | + | ++ | +++ | ||
| Normal group model group treatment group | 10 16 15 | 10 0 0 | 0 4 11 | 0 7 3 | 0 5 1 |
Annotate :-: no degeneration hepatocyte+: the degeneration hepatocyte accounts for the visual field＜1/3, ++: the degeneration hepatocyte accounts for visual field 1/3-2/3,
+++: degeneration hepatocyte accounts for the visual field＞2/3.
Model group compares with normal group: P＜0.05.
Table 3.
| Group | n | Fat drips the sxemiquantitative classification | |||
| - | + | ++ | +++ | ||
| Normal group model group treatment group | 10 16 15 | 10 0 0 | 0 0 1 | 0 4 10 | 0 12 4 |
Annotate :-: no fat drips ,+: fat drips and accounts for the visual field＜1/3, ++: fat drips and accounts for visual field 1/3-2/3,
+++: fat drips and accounts for the visual field＞2/3.
Model group compares with normal group: P＜0.05.
Table 4.
| Group | n | Oil red dyeing fatty liver fat titration classification | ||
| No fat drips | Bulla fat drips | Vesicle fat drips | ||
| Normal group model group treatment group | 10 16 15 | 10 0 0 | 0 16 0 | 0 0 15 |
Annotate: each more equal in twos P＜0.05 between three groups.
Table 5
| Group | Number of elements | Each organizes rat liver oil red dyeing area (%) |
| Normal group model group treatment group | 10 16 15 | 0 0.166±0.032 0.057±0.011* |
Annotate: compare * P＜0.01 with model group
Biochemistry detection result shows:
The active no significant difference of three groups of Serum ALT and AST, the serum levels of ALP of model group and treatment group and GGT activity, serum T BiL and TC content and hepatic tissue TG concentration all increase than normal group, but there was no significant difference between preceding 2 groups.
Table 6 is respectively to organize biochemical indicator testing result relatively (MEAN ± SD)).
Table 6.
| Group (n) | ALT (U/L) | AST (U/L ) | ALP (U/L) | GGT (U/L) | TBiL (μmol/L) | TC (mmol/L) | TG (mmol/L) |
| Normal group (10) model group (16) treatment group (15) | 167.2±12.4 166.0±19.5 165.8±38.3 | 80.1±16.9 100.1±31.7 82.2±32.8 | 34.9±5.4 51.1±2.9 47.9±4.4 | 223.8±38.4 261.7±53.3 268.3±36.6 | 2.9±1.0 3.7±1.0 3.5±1.1 | 53.6±7.3 71.3±9.0 70.0±6.5 | 0.99±0.17 2.40±0.62 2.50±0.53 |
Preparation of the present invention proves through experimental result, the body weight regulating liver-QI that can effectively alleviate the fatty liver rat is heavy, obviously reduces rat model intrahepatic fat deposition, alleviates the pathological change of hepatic cell fattydegeneration, the unusual liver function of fatty liver rat is not had obvious inhibitory action, do not meet quick and other untoward reaction.Prompting is more suitable for the health care prevention of simple fatty liver.The present invention can prepare the health food or the prophylactic agent of lipid-lowering weight-reducing and simple fatty liver.
Claims (4)
- But 1, the compound preparation that protects the liver of a kind of fat reducing, it is to be made by effective ingredient and pharmaceutical carrier, it is characterized in that described effective ingredient is made up of following raw materials by weight percent medicine component:Radix Ginseng 10-15%, Radix Salviae Miltiorrhizae 10-15%, Fructus Crataegi 15-25%, Rhizoma Alismatis 10-15%, Semen Cassiae 15-20%, Rhizoma Wenyujin Concisum 10-15%.
- 2, but the compound preparation that protects the liver by the described fat reducing of claim 1 is characterized in that, wherein the percentage by weight of each crude drug is: Radix Ginseng 15%, Radix Salviae Miltiorrhizae 10%, Fructus Crataegi 25%, Rhizoma Alismatis 15%, Semen Cassiae 20%, Rhizoma Wenyujin Concisum 15%.
- But 3, the preparation method of the compound preparation that protects the liver of the fat reducing of claim 1 is characterized in that by following method and step:Get crude drug Rhizoma Alismatis and Rhizoma Curcumae Longae and in apparatus,Soxhlet's, extract volatile oil, medicinal residues and all the other crude drug added 10 times of amounts of water for the first time with frying in shallow oil after extraction finished, and decocted 2h, incline and medical filtration, medicinal residues add 8 times of amounts of water again, decoct 1h, and inclining medical filtration, merge 2 times fried liquid, concentrate the volatile oil that the back adds Rhizoma Alismatis and Rhizoma Curcumae Longae, mixing is adjusted drug level.
- 4, by the preparation method of claim 3, it is characterized in that described drug level is adjusted into 0.835g/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101195784A CN100515480C (en) | 2006-12-13 | 2006-12-13 | Compound preparation for reducing fat deposit in liver and alleviating fatty degeneration of liver cell |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101195784A CN100515480C (en) | 2006-12-13 | 2006-12-13 | Compound preparation for reducing fat deposit in liver and alleviating fatty degeneration of liver cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1985978A true CN1985978A (en) | 2007-06-27 |
| CN100515480C CN100515480C (en) | 2009-07-22 |
Family
ID=38183007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101195784A Active CN100515480C (en) | 2006-12-13 | 2006-12-13 | Compound preparation for reducing fat deposit in liver and alleviating fatty degeneration of liver cell |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100515480C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101366882B (en) * | 2008-09-26 | 2010-04-21 | 茂祥集团吉林制药有限公司 | Compound formulation with function of reducing blood fat and blood sugar |
| CN101869687A (en) * | 2010-06-10 | 2010-10-27 | 银小龙 | Medicament for treating fatty liver and alcohol liver, and reducing blood lipid and aminotransferase |
| CN102357226B (en) * | 2007-08-07 | 2013-07-10 | 北京北大维信生物科技有限公司 | Application of Chinese herbal medicine turmeric extraction in preparation of drug with lipase activity inhibition effect |
| CN112826889A (en) * | 2021-03-04 | 2021-05-25 | 杭州市中医院 | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease |
| CN114392335A (en) * | 2021-12-10 | 2022-04-26 | 安发（福建）生物科技有限公司 | Traditional Chinese medicine composition with weight-losing and lipid-lowering effects and preparation method and application thereof |
-
2006
- 2006-12-13 CN CNB2006101195784A patent/CN100515480C/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102357226B (en) * | 2007-08-07 | 2013-07-10 | 北京北大维信生物科技有限公司 | Application of Chinese herbal medicine turmeric extraction in preparation of drug with lipase activity inhibition effect |
| CN101366882B (en) * | 2008-09-26 | 2010-04-21 | 茂祥集团吉林制药有限公司 | Compound formulation with function of reducing blood fat and blood sugar |
| CN101869687A (en) * | 2010-06-10 | 2010-10-27 | 银小龙 | Medicament for treating fatty liver and alcohol liver, and reducing blood lipid and aminotransferase |
| CN101869687B (en) * | 2010-06-10 | 2011-11-16 | 银小龙 | Medicament for treating fatty liver and alcohol liver, and reducing blood lipid and aminotransferase |
| CN112826889A (en) * | 2021-03-04 | 2021-05-25 | 杭州市中医院 | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease |
| CN114392335A (en) * | 2021-12-10 | 2022-04-26 | 安发（福建）生物科技有限公司 | Traditional Chinese medicine composition with weight-losing and lipid-lowering effects and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100515480C (en) | 2009-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078512B (en) | Pharmaceutical composition for improving fatigue and preparation method thereof | |
| CN102106957B (en) | Chinese medicinal composition for treating hyperlipidemia | |
| CN101332284B (en) | Chinese traditional medicine composition for treating ulcerative colitis and its preparation method | |
| CN102139084B (en) | Chinese medicinal composition for treating fatty liver and preparation method and application thereof | |
| CN100515480C (en) | Compound preparation for reducing fat deposit in liver and alleviating fatty degeneration of liver cell | |
| CN102671137B (en) | Medicine composition for treating diabetic nephropathy and preparation method of medicine composition | |
| CN101310751A (en) | Traditional Chinese medicine composition for replenishing qi and blood, preparation method and quality control method thereof | |
| CN107184892A (en) | Composition with blood-nourishing black hair effect and preparation method thereof | |
| CN101199668B (en) | Chinese medicine agent for treating alcohol fatty liver and preparing method thereof | |
| CN103948791B (en) | A kind of Chinese medicine composition of reducing blood lipid and preparation method thereof | |
| CN103749818B (en) | A kind of sealwort hypoglycemic health protection tea and preparation method thereof | |
| CN102488743A (en) | Chinese traditional medicine composition, preparation method thereof and Chinese traditional medicine preparation | |
| CN102048902B (en) | Hepatitis treating traditional Chinese medicine composition, extract and preparation method, application and formulation | |
| CN101919986B (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease | |
| CN104815316A (en) | Traditional Chinese medicine preparation for treating acute or chronic pancreatitis and preparation method thereof | |
| CN105267559B (en) | A kind of drug and preparation method thereof for treating diabete peripheral herve pathology | |
| CN104383447A (en) | Traditional Chinese medicine composition as well as preparation method and application thereof | |
| Chen et al. | Toxicity studies of rhizoma polygonati odorati | |
| CN106579392A (en) | Composition for alleviating delayed onset muscle soreness | |
| CN104958615B (en) | A kind of Chinese medicine composition of prevention and treatment II diabetes and preparation method thereof | |
| CN104524167A (en) | Traditional Chinese medicine preparation for treating liver cirrhosis and liver ascites and preparation method of traditional Chinese medicine preparation | |
| CN100409880C (en) | Mongolian medicine Baolier for treating hyperlipemia and method for preparing same | |
| CN102772732A (en) | Medicine composition for treating chronic liver disease | |
| CN103202976B (en) | Traditional Chinese medicine extract for treating myasthenia gravis and preparation method thereof | |
| CN101269152A (en) | Application of matrimony vine and black fungus in preparing fatty liver resistant medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: LB NATURE (SHANGHAI) CO., LTD. Free format text: FORMER NAME: SHANGHAI LAIBO BIO-CHEMICAL CO. LTD. |
|
| CP03 | Change of name, title or address |
Address after: 8, building 701, room 1, building 333, No. 200032, Guiping Road, Shanghai Patentee after: Laibo Industrial (Shanghai) Limited by Share Ltd Patentee after: Xu Lieming Address before: 200032 Shanghai City Wanping Road No. 2 Lane 99, room 1408 Patentee before: Shanghai Laibo Bio-chemical Co., Ltd. Patentee before: Xu Lieming |
|
| CP03 | Change of name, title or address |
Address after: 8, No. 1, building 200233, building 701, room 333, Guiping, Shanghai Co-patentee after: Xu Lieming Patentee after: Laibo cosmeceutical Technology (Shanghai) Limited by Share Ltd Address before: 8, building 701, room 1, building 333, No. 200032, Guiping Road, Shanghai Co-patentee before: Xu Lieming Patentee before: Laibo Industrial (Shanghai) Limited by Share Ltd |
|
| CP03 | Change of name, title or address |